Cargando…

Outcomes of the 340B Drug Pricing Program: A Scoping Review

IMPORTANCE: The 340B Drug Pricing Program requires manufacturers to offer discounted drug prices to support safety net hospitals and clinics (covered entities) providing care to low-income populations. Amid expansion, the program has received criticism and calls for reform. OBJECTIVE: To assess the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Knox, Ryan P., Wang, Junyi, Feldman, William B., Kesselheim, Aaron S., Sarpatwari, Ameet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665972/ https://www.ncbi.nlm.nih.gov/pubmed/37991784 http://dx.doi.org/10.1001/jamahealthforum.2023.3716

Ejemplares similares

Competition law and pricing among biologic drugs: the case of VEGF therapy for retinal diseases
por: Van de Wiele, Victor L, et al.
Publicado: (2022)

Competition and price among brand-name drugs in the same class: A systematic review of the evidence
por: Sarpatwari, Ameet, et al.
Publicado: (2019)

The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?
por: Sarpatwari, Ameet, et al.
Publicado: (2016)

Regulatory Solutions to the Problem of High Generic Drug Costs
por: Luo, Jing, et al.
Publicado: (2015)

Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs
por: Rome, Benjamin N., et al.
Publicado: (2021)

Analysis of risk evaluation and mitigation strategies for teratogenic drugs: Variation in primary and secondary prevention measures
por: Brown, Beatrice L., et al.
Publicado: (2023)

Patient and Caregiver Experiences With and Perceptions of Risk Evaluation and Mitigation Strategy Programs With Elements to Assure Safe Use
por: Sarpatwari, Ameet, et al.
Publicado: (2022)

Access to the 340B Drug Pricing Program: is there evidence of strategic hospital behavior?
por: Mulligan, Karen, et al.
Publicado: (2021)

Paying Physicians to Prescribe Generic Drugs and Follow-On Biologics in the United States
por: Sarpatwari, Ameet, et al.
Publicado: (2015)

Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019
por: Clemans-Cope, Lisa, et al.
Publicado: (2023)

Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016
por: Conti, Rena M., et al.
Publicado: (2019)

Association Between New 340B Program Participation and Commercial Insurance Spending on Outpatient Biologic Oncology Drugs
por: Chang, Jessica, et al.
Publicado: (2023)

Association of Beneficiary-Level Risk Factors and Hospital-Level Characteristics With Medicare Part B Drug Spending Differences Between 340B and Non-340B Hospitals
por: Li, Yufei, et al.
Publicado: (2022)

Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration
por: Feldman, Daniel, et al.
Publicado: (2022)

Trends in 340B Drug Pricing Program Contract Growth Among Retail Pharmacies From 2009 to 2022
por: Nikpay, Sayeh, et al.
Publicado: (2023)

The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine
por: Wang, Bo, et al.
Publicado: (2017)

Physician experiences with and perceptions of risk evaluation and mitigation strategy programs with elements to assure safe use
por: Sarpatwari, Ameet, et al.
Publicado: (2023)

Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program
por: Jones, Eric A., et al.
Publicado: (2019)

Assessment of US Pharmacies Contracted With Health Care Institutions Under the 340B Drug Pricing Program by Neighborhood Socioeconomic Characteristics
por: Lin, John K., et al.
Publicado: (2022)

Achieving high value care for all and the perverse incentives of 340B price agreements
por: Whittington, Melanie D., et al.
Publicado: (2018)

International reference pricing for prescription drugs: a landscape analysis
por: Rand, Leah Z, et al.
Publicado: (2021)

Public Approval of Exception From Informed Consent in Emergency Clinical Trials: A Systematic Review of Community Consultation Surveys
por: Feldman, William B., et al.
Publicado: (2019)

US public investment in development of mRNA covid-19 vaccines: retrospective cohort study
por: Lalani, Hussain S, et al.
Publicado: (2023)

Trends in Proportion of Medicare Part D Claims Subject to 340B Discounts, 2013-2020
por: Dickson, Sean, et al.
Publicado: (2023)

Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs: A Systematic Review and Pooled Analysis
por: Gyawali, Bishal, et al.
Publicado: (2019)

Comparison of Generic Prescribing Patterns Among 340B-Eligible and Non-340B Prescribers in the Medicare Part D Program
por: Dickson, Sean, et al.
Publicado: (2023)

COVID-19 antivirals must not affect HIV drug supply
por: Barber, Melissa, et al.
Publicado: (2022)

Projected spending for brand-name drugs in English primary care given US prices: a cross-sectional study
por: Liu, Michael, et al.
Publicado: (2020)

Affordability and Price Increases of New Cancer Drugs in Clinical Guidelines, 2007–2016
por: Hwang, Thomas J, et al.
Publicado: (2018)

Variation in Use of Lung Cancer Targeted Therapies Across State Medicaid Programs, 2020-2021
por: Roberts, Thomas J., et al.
Publicado: (2023)

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
por: Cherla, Avi, et al.
Publicado: (2021)

Variations in Use of Diabetes Drugs With Cardiovascular Benefits Among Medicaid Patients
por: Zhai, Mike Z., et al.
Publicado: (2022)

Association of Advisory Committee Votes With US Food and Drug Administration Decision-Making on Prescription Drugs, 2010-2021
por: Daval, C. Joseph Ross, et al.
Publicado: (2023)

Comparison of Price Index Methods and Drug Price Inflation Estimates for Hepatitis C Virus Medications
por: Mattingly, T. Joseph, et al.
Publicado: (2023)

Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
por: D’Andrea, Elvira, et al.
Publicado: (2019)

Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition
por: Dickson, Sean R., et al.
Publicado: (2021)

The 340B Program and Health Disparities Among Medicare Beneficiaries With Chronic Asthma
por: Tripp, Amanda S, et al.
Publicado: (2023)

National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval
por: Cliff, Edward R. Scheffer, et al.
Publicado: (2023)

Medicare Spending on Drugs With Accelerated Approval, 2015-2019
por: Rome, Benjamin N., et al.
Publicado: (2021)

Changes in Drug List Prices and Amounts Paid by Patients and Insurers
por: Yang, Eric J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0kmq37mk2l2n48pslhdn8g4qvm